A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology

被引:13
作者
Park, Kyungsoo [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Pharmacol, 50-1 Yonsei Ro, Seoul 03722, South Korea
关键词
Model-based approaches; drug development; drug treatment; chemotherapeutic drug; PROGRESSION-FREE SURVIVAL; SURROGATE END-POINT; PHARMACODYNAMIC MODEL; TUMOR-GROWTH; DISEASE PROGRESSION; CANCER-PATIENTS; CHEMOTHERAPY; SIZE; TIME; PHARMACOKINETICS;
D O I
10.3349/ymj.2017.58.1.1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Model-based approaches have emerged as important tools for quantitatively understanding temporal relationships between drug dose, concentration, and effect over the course of treatment, and have now become central to optimal drug development and tailored drug treatment. In oncology, the therapeutic index of a chemotherapeutic drug is typically narrow and a full dose-response relationship is not available, often because of treatment failure. Noting the benefits of model-based approaches and the low therapeutic index of oncology drugs, in recent years, modeling approaches have been increasingly used to streamline oncologic drug development through early identification and quantification of dose-response relationships. With this background, this report reviews publications that used model-based approaches to evaluate drug treatment outcome variables in oncology therapeutics, ranging from tumor size dynamics to tumor/biomarker time courses and survival response.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 43 条
  • [11] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [12] Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment
    Fetterly, Gerald J.
    Owen, Joel S.
    Stuyckens, Kim
    Passarell, Julie A.
    Zannikos, Peter
    Soto-Matos, Arturo
    Izquierdo, Miguel Angel
    Perez-Ruixo, Juan Jose
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 135 - 147
  • [13] Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer
    Frances, N.
    Claret, L.
    Bruno, R.
    Iliadis, A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1413 - 1419
  • [14] Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
    Friberg, LE
    Henningsson, A
    Maas, H
    Nguyen, L
    Karlsson, MO
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) : 4713 - 4721
  • [15] Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials
    Giessen, Clemens
    Laubender, Ruediger Paul
    Ankerst, Donna Pauler
    Stintzing, Sebastian
    Modest, Dominik Paul
    Mansmann, Ulrich
    Heinemann, Volker
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (01) : 225 - 235
  • [16] PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
    Hansson, E. K.
    Ma, G.
    Amantea, M. A.
    French, J.
    Milligan, P. A.
    Friberg, L. E.
    Karlsson, M. O.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (12):
  • [17] Hansson EK, 2013, CPT PHARMACOMETRICS
  • [18] Hansson EK, 2012, PHARMACOMETRIC MODEL
  • [19] A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving Capecitabine
    Henin, E.
    You, B.
    VanCutsem, E.
    Hoff, P. M.
    Cassidy, J.
    Twelves, C.
    Zuideveld, K. P.
    Sirzen, F.
    Dartois, C.
    Freyer, G.
    Tod, M.
    Girard, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (04) : 418 - 425
  • [20] Holford Nick, 2013, CPT Pharmacometrics Syst Pharmacol, V2, pe43, DOI 10.1038/psp.2013.18